bluebird bio Inc. (NASDAQ:BLUE) finished Thursday with a subtraction of -$0.2 to close at $5.97, a downside of -3.24 percent. An average of 18,720,240 shares of common stock have been traded in the last five days. There was a fall of -$1.12 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 9,296,465 shares traded, while the 50-day average volume stands at 8,513,198.
BLUE stock has increased by 1.36% in the last month. The company shares reached their 1-month lowest point of $5.42 on 09/19/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $2.87 and a high of $17.85 in 52 weeks. It has reached a new high 2 times so far this year and lost -40.24% or -$4.02 in price. In spite of this, the price is down -66.55% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
35 days have passed since bluebird bio Inc. (BLUE) last reported insider trading activity. Cole Jason, who is Chief Strategy & Financial Off, most recently acquired $14,194 shares at $5.53 per share on Aug 19. In this transaction, the insider spent $78,473. Chief Strategy & Financial Off, Cole Jason, disposed of 7,448 shares at a price of $4.39 on Aug 04. The insider now owns more than $32,707 worth of shares. Prior to that, President and CEO Obenshain Andrew went on to Sale 21,805 shares at $4.39 each on Aug 04. An amount of $95,754 was transacted.
bluebird bio Inc. (BLUE) stock’s beta is 1.09. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 84.41, the price-to-book (PB) ratio at 2.45.
Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at -$35.2 million compared to revenue of $3.66 million.
For the three-month period that ended March 30, bluebird bio Inc. had $51.01 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$100.14 million in the quarter, while revenues of -$122.15 million were shrunk -105.52%. The analyst consensus anticipated bluebird bio Inc.’s latest quarter earnings to come in at -$1.39 per share, but it turned out to be -$1.66, a -19.40% surprise. For the quarter, EBITDA amounted to -$106.06 million. Shareholders own equity worth $77.12 million.
From a technical analysis perspective, let’s take a brief look at bluebird bio Inc. (BLUE) price momentum. RSI 9-day as of the close on 22 September was 42.96%, suggesting the stock is Neutral, with historical volatility in this time frame at 129.19%.
As of today, BLUE’s price is $6.25 -15.80% or -$1.12 from its 5-day moving average. BLUE is currently trading -5.24% lower than its 20-day SMA and +61.79% higher than its 100-day SMA. However, the stock’s current price level is +13.28% above the SMA50 and -43.84% below the SMA200.
The stochastic %K and %D were 45.69% and 45.60%, respectively, and the average true range (ATR) was 0.70. With the 14-day stochastic at 27.52% and the average true range at 0.68, the RSI (14) stands at 46.75%. The stock has reached -0.26 on the 9-day MACD Oscillator while the 14-day reading was at -0.36.
Barclays upgraded bluebird bio Inc. (NASDAQ: BLUE) to a an Equal weight rating in its most recent analyst report. Previously, the stock was rated as an Underweight. The consensus rating for bluebird bio Inc. (BLUE) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell BLUE, while 8 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 0 others rate it as a “buy”.
What is BLUE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $10.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for bluebird bio Inc. (BLUE) stock is $7.78.